Home › Trials › NCT06289374
Clinical trial Recruiting at 1 site Observational Ages 18 to 90

Assessing biomarkers after surgery for oesophagogastric cancer

Official title: The LABS Study: Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery (BIORESOURCE 2: Longitudinal)

Run by Imperial College London · NCT06289374 · Data updated 2026-11-12

This study is trying to find out if certain biological markers in patients who had surgery for oesophageal and gastric cancer can help predict how well they will respond to treatment and their chances of recovery.

More Gastric Adenocarcinoma trials

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment100 (estimated)
SponsorImperial College London
Academic / other
Locations1 site (London)
StatusRecruiting
StartedFebruary 2025
Main results expectedJune 2028
Study endsJune 2029
Registry record updatedFebruary 19, 2025
Trial IDNCT06289374 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-90 with biopsy-proven gastric or oesophageal adenocarcinoma who are part of the BIORESOURCE 1 cohort.

Probably not a fit

Patients with oesophageal squamous cell carcinoma or those with a history of other cancers within the last five years may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with oesophageal and gastric adenocarcinoma who have undergone surgery. It aims to collect matched biosamples during the follow-up period to identify biomarkers that could predict treatment response, recurrence, and long-term prognosis. The study builds on the existing BIORESOURCE 1 project, which has already established a comprehensive resource of samples from similar patients. By understanding the relationship between the cancer-specific microbiome and inflammation, the study seeks to enhance knowledge of cancer progression.

Why it matters

Potential benefit: If successful, this study could lead to improved methods for predicting treatment outcomes and recurrence in patients with oesophagogastric cancer.

How similar studies have gone: While this study builds on previous research, the specific approach of longitudinal biomarker assessment in this context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Aged 18-90 years at the time of initial recruitment
* Gastric/oesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into BIORESOURCE 1

Exclusion Criteria:

* Oesophageal squamous cell carcinoma
* Previous oesophageal and gastric resection
* History of another cancer within five years. If a new other cancer type is diagnosed within the sampling time frame, no further samples will be taken.
* Participants with co-morbidities preventing breath collection
* Unable or unwilling to provide informed written consent
* Pregnant women

Where it's running

  • Imperial College Healthcare NHS Trust
    London, United Kingdom     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Oesophageal Adenocarcinoma 6Gastric Adenocarcinoma 71Imperial College London 92
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.